Zydus Lifesciences, Formycon, FYB206, Keytruda Biosimilar, Pembrolizumab, FDA BLA Review, Biosimilar Development, Oncology, Cancer Immunotherapy, PD-1 Inhibitor, Biologics License Application

Ahmedabad, India, and Planegg-Martinsried, Germany, October 13, 2026 Zydus Lifesciences Limited and Formycon AG have announced that the U.S....